Press release
August 10, 2026
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics, Inc. (DMRA)
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at the European Hematology Association (EHA) 2026 Congress, showcasing best-in-class